T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …
Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
Abstract According to WHO (World Health Organization) reports, more than 770,000 people
died from HIV and almost 1.7 million people becoming newly infected in the worldwide in …
died from HIV and almost 1.7 million people becoming newly infected in the worldwide in …
Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative
The receptor binding domain (RBD) of SARS-CoV-2 is the primary target of neutralizing
antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion …
antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion …
HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge
The oral mucosa is an attractive site for mucosal vaccination, however the thick squamous
epithelium limits antigen uptake. Here we utilize a modified needle-free injector to deliver …
epithelium limits antigen uptake. Here we utilize a modified needle-free injector to deliver …
A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques
The rising global HIV-1 burden urgently requires vaccines capable of providing
heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming …
heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming …
V2-specific antibodies in HIV-1 vaccine research and natural infection: controllers or surrogate markers
R Duerr, MK Gorny - Vaccines, 2019 - mdpi.com
Most human immunodeficiency virus (HIV) vaccine trials have lacked efficacy and empirical
vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of …
vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of …
[HTML][HTML] Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or
neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion …
neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion …
A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria
Human malaria is a pathogenic disease mainly caused by Plasmodium falciparum, which
was responsible for about 405,000 deaths globally in the year 2018. To date, several …
was responsible for about 405,000 deaths globally in the year 2018. To date, several …
Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen
The RV144 HIV-1 clinical trial demonstrated modest vaccine efficacy and identified IgG
antibodies against the Env V1V2 loop that inversely correlated with risk of infection. Based …
antibodies against the Env V1V2 loop that inversely correlated with risk of infection. Based …
Bridging vaccine-induced HIV-1 neutralizing and effector antibody responses in rabbit and rhesus macaque animal models
J Pollara, DI Jones, T Huffman, RW Edwards… - Journal of …, 2019 - Am Soc Microbiol
Studies in animal models are essential prerequisites for clinical trials of candidate HIV
vaccines. Small animals, such as rabbits, are used to evaluate promising strategies prior to …
vaccines. Small animals, such as rabbits, are used to evaluate promising strategies prior to …